Rituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of FcγRIIB receptors

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 2, 2012, Pages 505-513

  Wang, Li Hua ^a   Wang, Ning ^a,b   Lu, Xiao Yu ^a,b   Liu, Bing Chen ^b   Yanda, Murali K ^b   Song, John Z ^b   Dai, Helena M ^b   Sun, Yu Liang ^b   Bao, Hui Fang ^b   Eaton, Douglas C ^b   Ma, He Ping ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Confocal microscopy; Fc receptor; Patch clamp technique; Rituximab; Voltage dependent potassium channel

Indexed keywords

FC RECEPTOR IIB; POTASSIUM CHANNEL KV1.3; RITUXIMAB;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; B LYMPHOMA CELL; CHANNEL GATING; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOMA CELL; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHOLERA TOXIN; HUMANS; KV1.3 POTASSIUM CHANNEL; LYMPHOMA, B-CELL; MICE; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; QUININE; RECEPTORS, IGG;

EID: 84862804030     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.11.012     Document Type: Article

References (45)

1. Amoroso A., Hafsi S., Militello L., Russo A.E., Soua Z., Mazzarino M.C., Stivala F., Libra M. Understanding rituximab function and resistance: implications for tailored therapy. Front. Biosci. 2011, 16:770-782.
2. Beeton C., Pennington M.W., Wulff H., Singh S., Nugent D., Crossley G., Khaytin I., Calabresi P.A., Chen C.Y., Gutman G.A., Chandy K.G. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol. Pharmacol. 2005, 67:1369-1381.
3. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:13942-13947.
4. Beeton C., Wulff H., Standifer N.E., Azam P., Mullen K.M., Pennington M.W., Kolski-Andreaco A., Wei E., Grino A., Counts D.R., Wang P.H., LeeHealey C.J., Andrews S., Sankaranarayanan A., Homerick D., Roeck W.W., Tehranzadeh J., Stanhope K.L., Zimin P., Havel P.J., Griffey S., Knaus H.G., Nepom G.T., Gutman G.A., Calabresi P.A., Chandy K.G. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17414-17419.
5. Berinstein N.L., Grillo-Lopez A.J., White C.A., Bence-Bruckler I., Maloney D., Czuczman M., Green D., Rosenberg J., McLaughlin P., Shen D. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 1998, 9:995-1001.
6. Beum P.V., Lindorfer M.A., Taylor R.P. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J. Immunol. 2008, 181:2916-2924.
7. Chao M.P., Alizadeh A.A., Tang C., Myklebust J.H., Varghese B., Gill S., Jan M., Cha A.C., Chan C.K., Tan B.T., Park C.Y., Zhao F., Kohrt H.E., Malumbres R., Briones J., Gascoyne R.D., Lossos I.S., Levy R., Weissman I.L., Majeti R. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010, 142:699-713.
8. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
9. Czuczman M.S., Gregory S.A. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk. Lymphoma 2010, 51:983-994.
10. Daniels I., Abulayha A.M., Thomson B.J., Haynes A.P. Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis 2006, 11:1013-1023.
11. Dhodapkar K.M., Banerjee D., Connolly J., Kukreja A., Matayeva E., Veri M.C., Ravetch J.V., Steinman R.M., Dhodapkar M.V. Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J. Exp. Med. 2007, 204:1359-1369.
12. Dias C.R., Jeger S., Osso J.A., Muller C., De P.C., Hohn A., Waibel R., Schibli R. Radiolabeling of rituximab with (188)Re and (99m)Tc using the tricarbonyl technology. Nucl. Med. Biol. 2011, 38:19-28.
13. Dutertre C.A., Bonnin-Gelize E., Pulford K., Bourel D., Fridman W.H., Teillaud J.L. A novel subset of NK cells expressing high levels of inhibitory FcγRIIB modulating antibody-dependent function. J. Leukoc. Biol. 2008, 84:1511-1520.
14. Ernst J.A., Li H., Kim H.S., Nakamura G.R., Yansura D.G., Vandlen R.L. Isolation and characterization of the B-cell marker CD20. Biochemistry 2005, 44:15150-15158.
15. Garcia-Calvo M., Leonard R.J., Novick J., Stevens S.P., Schmalhofer W., Kaczorowski G.J., Garcia M.L. Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels. J. Biol. Chem. 1993, 268:18866-18874.
16. Hofmeister J.K., Cooney D., Coggeshall K.M. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol. Dis. 2000, 26:133-143.
17. Hunter S., Indik Z.K., Kim M.K., Cauley M.D., Park J.G., Schreiber A.D. Inhibition of Fcγ receptor-mediated phagocytosis by a nonphagocytic Fcγ receptor. Blood 1998, 91:1762-1768.
18. Ichiyama T., Ueno Y., Hasegawa M., Ishikawa Y., Matsubara T., Furukawa S. Intravenous immunoglobulin does not increase FcγRIIB expression on monocytes/macrophages during acute Kawasaki disease. Rheumatology (Oxford) 2005, 44:314-317.
19. Idusogie E.E., Presta L.G., Gazzano-Santoro H., Totpal K., Wong P.Y., Ultsch M., Meng Y.G., Mulkerrin M.G. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 2000, 164:4178-4184.
20. Jacob A., Cooney D., Tridandapani S., Kelley T., Coggeshall K.M. FcγRIIb modulation of surface immunoglobulin-induced Akt activation in murine B cells. J. Biol. Chem. 1999, 274:13704-13710.
21. Kohrt H.E., Houot R., Goldstein M.J., Weiskopf K., Alizadeh A.A., Brody J., Muller A., Pachynski R., Czerwinski D., Coutre S., Chao M.P., Chen L., Tedder T.F., Levy R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011, 117:2423-2432.
22. Lefebvre M.L., Krause S.W., Salcedo M., Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J. Immunother. 2006, 29:388-397.
23. Lim S.H., Vaughan A.T., Ashton-Key M., Williams E.L., Dixon S.V., Chan C.H., Beers S.A., French R.R., Cox K.L., Davies A.J., Potter K.N., Mockridge C.I., Oscier D.G., Johnson P.W., Cragg M.S., Glennie M.J. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011, 118:2530-2540.
24. Maenaka K., van der Merwe P.A., Stuart D.I., Jones E.Y., Sondermann P. The human low affinity Fcgamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J. Biol. Chem. 2001, 276:44898-44904.
25. Maloney D.G., Grillo-Lopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., Janakiraman N., Foon K.A., Liles T.M., Dallaire B.K., Wey K., Royston I., Davis T., Levy R. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
26. Natsume A., Shimizu-Yokoyama Y., Satoh M., Shitara K., Niwa R. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity. Cancer Sci. 2009, 100:2411-2418.
27. Nguyen T.H., Havari E., McLaren R., Zhang M., Jiang Y., Madden S.L., Roberts B., Kaplan J., Shankara S. Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes. Leuk. Lymphoma 2011, 10.3109/10428194.2011.623253.
28. Partiseti M., Korn H., Choquet D. Pattern of potassium channel expression in proliferating B lymphocytes depends upon the mode of activation. J. Immunol. 1993, 151:2462-2470.
29. Piccioni M., Monari C., Bevilacqua S., Perito S., Bistoni F., Kozel T.R., Vecchiarelli A. A critical role for FcgammaRIIB in up-regulation of Fas ligand induced by a microbial polysaccharide. Clin. Exp. Immunol. 2011, 165:190-201.
30. Pievani A., Belussi C., Klein C., Rambaldi A., Golay J., Introna M. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood 2011, 117:510-518.
31. Rangaraju S., Chi V., Pennington M.W., Chandy K.G. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis. Expert Opin. Ther. Targets 2009, 13:909-924.
32. Rankin C.T., Veri M.C., Gorlatov S., Tuaillon N., Burke S., Huang L., Inzunza H.D., Li H., Thomas S., Johnson S., Stavenhagen J., Koenig S., Bonvini E. CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 2006, 108:2384-2391.
33. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., Anderson D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
34. Sarmay G., Koncz G., Gergely J. Human type II Fcgamma receptors inhibit B cell activation by interacting with the p21(ras)-dependent pathway. J. Biol. Chem. 1996, 271:30499-30504.
35. Schmitz A., Sankaranarayanan A., Azam P., Schmidt-Lassen K., Homerick D., Hansel W., Wulff H. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol. Pharmacol. 2005, 68:1254-1270.
36. Shan D., Ledbetter J.A., Press O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998, 91:1644-1652.
37. Smith K.G., Clatworthy M.R. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 2010, 10:328-343.
38. Su K., Yang H., Li X., Li X., Gibson A.W., Cafardi J.M., Zhou T., Edberg J.C., Kimberly R.P. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J. Immunol. 2007, 178:3272-3280.
39. + channel in T lymphocytes upon Fas stimulation. J. Biol. Chem. 1996, 271:20465-20469.
40. Turzanski J., Daniels I., Haynes A.P. Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Br. J. Haematol. 2009, 145:137-140.
41. + channel mediates B lymphoma cell cycle progression induced by serum. Pflugers Arch. 2007, 454:945-956.
42. Wulff H., Calabresi P.A., Allie R., Yun S., Pennington M., Beeton C., Chandy K.G. The voltage-gated Kv1.3 channel in effector memory T cells as new target for MS. J. Clin. Invest. 2003, 111:1703-1713.
43. + channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J. Immunol. 2004, 173:776-786.
44. + channels in human B lymphoma cells. J. Membr. Biol. 2002, 188:97-105.
45. Zhuang Y., Xu W., Shen Y., Li J. Fcgamma receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Clin. Lymphoma Myeloma Leuk. 2010, 10:347-352.